Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis

OBJECTIVE: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targeted therapies for PsA through network meta-analysis (NMA). The objective of this NMA update was to include new guselkumab COSMOS trial data, and two key comparators: the IL-23 inhibitor risankizumab an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, McInnes, Iain B, Tam, Lai-Shan, Rajalingam, Raji, Peterson, Steve, Hassan, Fareen, Chakravarty, Soumya D, Contré, Christine, Armstrong, Alison, Boehncke, Wolf-Henning, Ritchlin, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Systematic Review and Meta Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070072/
https://www.ncbi.nlm.nih.gov/pubmed/36102818
http://dx.doi.org/10.1093/rheumatology/keac500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070072/
https://www.ncbi.nlm.nih.gov/pubmed/36102818
http://dx.doi.org/10.1093/rheumatology/keac500

Ejemplares similares